检索结果-南通市图书馆

Mechanism Underlying Increase of the Serum Magnesium Concentration Observed Following Treatment with Sodium-Glucose cotransporter 2 Inhibitors

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Journal of Diabetes Mellitus 2017年第4期7卷 241-248页

作者： Yasuhiro Sasaki Keiko Koyano Shuhei Iida Tatsuo Yanagawa Department of Medicine Nerima General Hospital Tokyo Japan Public Interest Incorporated Foundation Tokyo Healthcare Foundation Institute for Healthcare Quality Improvement Tokyo Japan

Aim: The EMPA-REG OUTCOME study reported that the sodium-glucose cotransporter 2 inhibitor (SGLT2-i) suppressed cardiovascular (CV) events in patients with type 2 diabetes;we recently suggested that increase of the serum magnesium (Mg) by SGLT2-i’s can, in part, explain this reduction. The objective of this study was to elucidate the mechanism underlying the elevation of the serum Mg level induced by treatment with SGLT2-i’s. Methods: We analyzed the data of 37 patients with type 2 diabetes who underwent clinical evaluation and laboratory assessment at baseline and the end of 3 months. To investigate the relationship between the changes in the serum Mg concentrations during 3 months’ treatment (ΔMg) and other variables, we carried out simple linear regression analysis and multiple linear regression analysis. Results: Three months’ treatment with the SGLT2-i resulted in a significant improvement of the body weight (BW), BMI, hemoglobin A1c (HbA1c), and fasting plasma glucose levels. The serum Mg increased significantly. Simple linear regression analysis revealed an association between the ΔMg and the serum triglyceride, serum Mg at baseline, change of the BW (ΔBW), and change of the HbA1c. Multiple linear regression analysis revealed a significant association between the ΔMg and the serum Mg level at the baseline (r = -0.55, P Conclusion: Our study revealed that a lower serum Mg level at the baseline and BW reduction were significantly associated with an increase in the serum Mg following 3 months’ treatment with SGLT2-i’s.

关键词： Diabetes Magnesium Cardiovascular Events Sodium-Glucose cotransporter 2 Inhibitors The EMPA-REG OUTCOME Study

Ipragliflozin: A novel sodium-glucose cotransporter 2 inhibitor developed in Japan

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Diabetes 2015年第1期6卷 136-144页

作者： Tsuyoshi Ohkura Division of Cardiovascular Medicine Endocrinology and Metabolism Department of Molecular Medicine and Therapeutics Tottori University Faculty of Medicine

Sodium-glucose cotransporter 2(SGLT2) inhibition induces glucosuria and decreases blood glucose levels in diabetic patients and lowers hypoglycemic risk. SGLT1 is expressed in the kidney and intestine; SGLT1 inhibition causes abdominal symptoms such as diarrhea and reduces incretin secretion. Therefore, SGLT2 selectivity is important. Ipragliflozin is highly selective for SGLT2. In type 2 diabetes mellitus(T2DM), urinaryglucose excretion increased to 90 g/24 h after 28 d of treatment with ipragliflozin 300 mg/d. Twelve weeks of ipragliflozin 50 mg/d vs placebo reduced glycated hemoglobin and body weight by 0.65% and 0.66 kg, respectively, in Western T2 DM patients, and by 1.3% and 1.89 kg, respectively, in Japanese patients. Ipragliflozin(highly selective SGLT2 inhibitor) improves glycemic control and reduces body weight and lowers hypoglycemic risk and abdominal symptoms. Ipragliflozin can be a novel anti-diabetic and antiobesity agent.

关键词： Sodium-glucose cotransporter 2 inhibitor Type 2 diabetes mellitus Ipragliflozin Japan

Effects of glucose-lowering agents on cardiorespiratory fitness

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Diabetes 2018年第12期9卷 230-238页

作者： Hidetaka Hamasaki Endocrinology and Metabolism Internal Medicine Hamasaki Clinic

Exercise therapy is essential for the management of type 2 diabetes(T2 D). However, patients with T2 D show lower physical activity and reduced cardiorespiratory fitness than healthy individuals. It would be ideal for clinicians to co-prescribe glucose-lowering agents that improve cardiorespiratory fitness or exercise capacity in conjunction with exercise therapy. Metformin does not improve cardiorespiratory fitness and may attenuate any beneficial effect of exercise in patients with T2 D. In contrast, thiazolidinediones appear to improve cardiorespiratory fitness in patients with T2 D. Although evidence is limited, sodium–glucose cotransporter 2(SGLT2) inhibitors may improve cardiorespiratory fitness in patients with heart failure, and the effect of glucagon-like peptide-1(GLP-1) receptor agonists on cardiorespiratory fitness is controversial. Recent clinical trials have shown that both SGLT2 inhibitors and GLP-1 receptor agonists exert a favorable effect on cardiovascular disease. It becomes more important to choose drugs that have beneficial effects on the cardiovascular system beyond glucose-lowering effects. Further studies are warranted to determine an ideal glucose-lowering agent combined with exercise therapy for the treatment of T2 D.

关键词： Type 2 diabetes Glucagon-like peptide l receptor agonist Cardiorespiratory fitness Exercise capacity Metformin Thiazolidinedione Sodium-glucose cotransporter 2 inhibitors

Bilateral gangrene of fingers in a patient on empagliflozin: First case report

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Diabetes 2019年第2期10卷 133-136页

作者： Rajasree Pai Ramachandra Pai Raghesh Varot Kangath Endocrinology and Metabolism and Internal Medicine San Francisco VA Medical Center Santa Rosa CA 95492 United States Infectious Diseases and Internal Medicine San Francisco VA Medical Center Santa Rosa CA 95492 United States

BACKGROUND Sodium glucose cotransporter 2(SGLT2)inhibitors use has been associated with toe amputations and non-healing ulcers and gangrene mostly of lower *** are no case reports about association of Empagliflozin with finger ulcers or *** is the first case report of Empagliflozin(Jardiance)an SGLT2 inhibitor causing gangrene of fingers and second case in literature about any SGLT2 inhibitor causing gangrene of upper *** SUMMARY A 76-year-old man with type 2 diabetes mellitus sustained minimal trauma to both middle fingers,which started *** was started on empagliflozin a week later for management of type 2 diabetes mellitus and started developing gangrene to both middle finger tips along with neuropathic pain which worsened over the course of next four *** were negative for vascular insufficiency,infection and vasculitis and imaging of hand was *** of empagliflozin slowed progression of gangrene and caused symptomatic improvement with reduction in neuropathic *** This case report suggests possible association of empagliflozin and finger gangrene and recommends that more research and awareness among clinicians is needed in this area.

关键词： Empagliflozin Finger gangrene Non-healing ulcer Type 2 diabetes mellitus Sodium glucose cotransporter 2 inhibitor Jardiance Case report

Crosstalk between gut microbiota and antidiabetic drug action

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Diabetes 2019年第3期10卷 154-168页

作者： Yevheniia Kyriachenko Tetyana Falalyeyeva Oleksandr Korotkyi Nataliia Molochek Nazarii Kobyliak Educational and Scientific Centre “Institute of Biology and Medicine” Taras Shevchenko National University of Kyiv Kyiv 01601 Ukraine Endocrinology Department Bogomolets National Medical University Kyiv 01601 Ukraine

Type 2 diabetes (T2D) is a disorder characterized by chronic inflated blood glucose levels (hyperglycemia), at first due to insulin resistance and unregulated insulin secretion but with tendency towards global spreading. The gut microbiota is recognized to have an influence on T2D, although surveys have not formed a clear overview to date. Because of the interactions between gut microbiota and host homeostasis, intestinal bacteria are believed to play a large role in various diseases, including metabolic syndrome, obesity and associated disease. In this review, we highlight the animal and human studies which have elucidated the roles of metformin,α-glucosidase inhibitors, glucagon-like peptide-1 agonists, peroxisome proliferator-activated receptors γ agonists, inhibitors of dipeptidyl peptidase-4, sodium/glucose cotransporter inhibitors, and other less studied medications on gut microbiota. This review is dedicated to one of the most widespread diseases, T2D, and the currently used antidiabetic drugs and most promising new findings. In general, the gut microbiota has been shown to have an influence on host metabolism, food consumption, satiety, glucose homoeostasis, and weight gain. Altered intestinal microbiota composition has been noticed in cardiovascular diseases, colon cancer, rheumatoid arthritis, T2D, and obesity. Therefore, the main effect of antidiabetic drugs is on the microbiome composition, basically increasing the short-chain fatty acids-producing bacteria, responsible for losing weight and suppressing inflammation.

关键词： Type 2 diabetes Gut microbiota Metformin α-glucosidase inhibitors Glucagon-like peptide-1 agonists Peroxisome proliferator-activated receptors γ agonists Dipeptidyl peptidase-4 inhibitors Sodium/glucose cotransporter inhibitors

Latent Autoimmune Diabetes in Adults Complicated by Persistent Isolated Glucosuria in the Absence of Hyperglycemia

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Case Reports in Clinical Medicine 2017年第5期6卷 133-136页

作者： Kosuke Inoue Yuya Tsurutani Chiho Sugisawa Sachiko Suematsu Jun Saito Masao Omura Tetsuo Nishikawa Endocrinology and Diabetes Center Yokohama Rosai Hospital Yokohama Japan

Latent autoimmune diabetes in adults (LADA) is an autoimmune diabetes of adult-onset with the presence of diabetes associated autoantibodies. Familial renal glucosuria (FRG) is an inherited renal tubular disorder that causes persistent isolated glucosuria in the absence of hyperglycemia. We report a novel case of LADA and certain FRG. A 44-year-old man was admitted to our hospital for uncontrolled diabetes. Before admission, he had never suffered from diabetic coma and showed an improvement in HbA1c only with diet therapy. His HbA1c was 11.9% (107 mmol/mol), and anti-glutamic acid decarboxylase antibody was 13.0 U/mL. A glucagon stimulation test showed the decrease of insulin secretion: plasma C-peptide (CPR) 0 min, 0.69 ng/mL;CPR 6 min, 0.90 ng/mL. Analysis of genomic DNA revealed a novel heterozygous mutation in the SGLT2 coding gene, SLC5A2 (c.875G >A, ***292Tyr), which was assessed as probably damaging with a score of 0.998 (sensitivity: 0.27;specificity: 0.99) by an in silico analysis. Therefore, he was diagnosed with LADA and certain FRG. He has not shown any symptoms and his HbA1c improved to 6.4% (46 mmol/mol) three months after the introduction of insulin therapy. Our case clearly implies the clinical effectiveness of SGLT2 inhibition in patients with LADA.

关键词： Latent Autoimmune Diabetes in Adults (LADA) Familial Renal Glucosuria (FRG) SLC5A2 Mutation Sodium-Glucose cotransporter 2 (SGLT2) Insulin Therapy

Perspective of future drugs targeting sterile 20/SPS1-related proline/alanine-rich kinase for blood pressure control

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Cardiology 2015年第6期7卷 306-310页

作者： Gen-Min Lin Pang-Yen Liu Ching-Fen Wu Wen-Been Wang Chih-Lu Han Department of Medicine Hualien Armed Forces General Hospital Division of Cardiology Department of Internal MedicineTri-Service General HospitalNational Defense Medical Center Department of Internal Medicine Mennorite Christian Hospital Department of Medicine Tri-Service General Hospital-Song Shan Branch 105 Department of Medicine Taipei Veterans General Hospital

According to a genome-wide association study,intronic SNPs within the human sterile 20/SPS1-related proline/alanine-rich kinase(SPAK) gene was linked to 20% of the general population and may be associated with elevated blood pressure. As cell volume changes,mammalian SPAK kinases respond to phosphorylate and regulate cation-coupled chloride co-transporter activity. To our knowledge,phosphorylation of upstream with-no-lysine(K)(WNK) kinases would activate SPAK kinases. The activation of WNK-OSR1/SPAK cascade on the kidneys and aortic tissue is related to the development of hypertension. Several regulators of the WNK pathway such as the Kelch kinase protein 3-Cullin 3 E3 ligase,hyperinsulinemia,and low potassium intake to mediate hypertension have been identified. In addition,the SPAK kinases may affect the action of renin-angiotensin-aldosterone system on blood pressure as well. In 2010,two SPAK knock-in and knock-out mouse models have clarified the pathogenesis of lowering blood pressure by influencing the receptors on the kidneys and aortic smooth muscle. More recently,two novel SPAK inhibitors for mice,Stock 1S-14279 and Closantel were discovered in 2014. Targeting of SPAK seems to be promising for future antihypertensive therapy. Therefore we raised some viewpoints for the issue for the antihypertensive therapy on the SPAK(gene or kinase).

关键词： With-no-lysine(K) kinase Oxidative stressresponsive kinase 1/SPS1-related proline/alaninerich kinase kinase Na-Cl co-transporter Na+-K+-2Cl(-) cotransporter Hypertension